Investigational drug · Phase 3
MT1013
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis, Secondary Hyperparathyroidism, Chronic Kidney Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
6
Any phase or sponsor naming "MT1013"
First trial start
2024
Jun 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT1013", any sponsor or status.
Conditions studied
As listed on its trial records.
- Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
- Secondary Hyperparathyroidism, Chronic Kidney Disease
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "MT1013" as an intervention, largest first.
- Study of MT1013 for the Treatment of Patients With Secondary HyperparathyroidismPivotal-lookingRecruiting
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07122401 · 424 participants (planned) · Start Sep 30, 2025 · Primary completion Nov 26, 2026
Drug: MT1013; Cinacalcet · For: Secondary Hyperparathyroidism, Chronic Kidney Disease
Sites: Shanghai, China
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT06976177 · 310 participants (planned) · Start Jun 7, 2024 · Primary completion Aug 19, 2025
Drug: MT1013 · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Hangzhou, China
- MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney DiseasePivotal-lookingCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT06690242 · 115 participants · Start Nov 4, 2024 · Primary completion Aug 30, 2025
Drug: MT1013; MT1013 and 2 more · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Hangzhou, China
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT06747247 · 98 participants · Start Apr 7, 2023 · Primary completion May 12, 2025
Drug: Long-term Dosing Cohort; Single ascending doses of MT1013 and 1 more · For: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Sites: Hangzhou, China
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT04783090 · 40 participants · Start Jun 28, 2021 · Primary completion Dec 31, 2021
Drug: MT1013 · For: Healthy Volunteer
Sites: Cypress, California
- A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary HyperparathyroidismCompleted
Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
NCT07284043 · 6 participants · Start Nov 27, 2025 · Primary completion May 14, 2026
Drug: [14C] MT1013/MT1013 Injection · For: Hemodialysis Subjects With Secondary Hyperparathyroidism
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
- SHR6508Phase 32 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. · Secondary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.